PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

Abstract

Clinical and MRI benefit continued for both doses up to 4 years, with evidence of dose response. Outcomes were consistently better for patients treated for 4 years than for patients in crossover groups. Efficacy decreased with neutralizing antibody formation.